within Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CA01_Dihydroergotamine;

model Dihydroergotamine
  extends Pharmacolibrary.Drugs.ATC.N.N02CA01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N02CA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dihydroergotamine is an ergot alkaloid medication primarily used for the treatment of migraine headaches and cluster headaches. It acts as a vasoconstrictor of intracranial arteries, and as an agonist at serotonin (5-HT1) receptors. It is approved and still in use for acute migraine attacks by several regulatory agencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Bodie, S, et al., &amp; Wasilewski, MM (2024). Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults. <i>Headache</i> 64(6) 643–651. DOI:<a href=&quot;https://doi.org/10.1111/head.14731&quot;>10.1111/head.14731</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38717120/&quot;>https://pubmed.ncbi.nlm.nih.gov/38717120</a></p></li><li><p>Kanto, J, et al., &amp; Siirtola, T (1981). Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 19(3) 127–130. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7228454/&quot;>https://pubmed.ncbi.nlm.nih.gov/7228454</a></p></li><li><p>Kanto, J, et al., &amp; Mäntylä, R (1980). The pharmacokinetics of dihydroergotamine in the beagle dog after a single intravenous injection and after a continuous intravenous infusion. <i>Acta pharmacologica et toxicologica</i> 46(4) 241–244. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0773.1980.tb02448.x&quot;>10.1111/j.1600-0773.1980.tb02448.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7368942/&quot;>https://pubmed.ncbi.nlm.nih.gov/7368942</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dihydroergotamine;
